Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?
Cardiovascular diseases are common, accounting for approximately 17.3 million global deaths annually. Substantial evidence exists for numerous risk factors including dyslipidemia, smoking, arterial hypertension, diabetes, and abdominal obesity. Numerous biomarkers have previously been reported in acute coronary syndromes, relating to both inflammation or myocardial damage.
Anti-beta-1-adrenergic receptor antibodies (anti-β1AR Ab) were first identified in the 1980s suggesting their possible influence on cardiac anti-β1AR Ab activity and adenylate cyclase activity. They have been mainly reported in association with cardiomyopathy, heart failure and ischemic heart disease.
The aim of this study was to measure anti-β1AR Ab in patients with confirmed acute coronary syndromes and compare levels to those in both healthy controls and patients with atherosclerosis in the absence of an acute coronary syndromes.
Lower anti-β1AR Ab concentrations appear to characterize acute coronary syndromes phenotypes and could serve as diagnostic and prognostic markers independent from traditional risk factors for atherosclerosis.
Mehr erfahren Sie hier!